Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.
Frequently asked questions
What sector does Arch Biopartners Inc (ARCH) operate in?
Arch Biopartners Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Arch Biopartners Inc (ARCH) current stock price?
As of the latest data, Arch Biopartners Inc stock price is CA$1.06, with a previous close of CA$1.10. Arch Biopartners Inc lost -CA$0.04 in the last trading session, representing a -3.64% loss.
What is Arch Biopartners Inc (ARCH) current market capitalization?
Arch Biopartners Inc market cap is approximately 72.01 million.
What is Arch Biopartners Inc (ARCH) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.04.
Does Arch Biopartners Inc (ARCH) pay dividends?
No. Arch Biopartners Inc does not pay a dividend.
When is Arch Biopartners Inc (ARCH) next earnings report?
Arch Biopartners Inc is expected to release its next earnings report on June 30, 2026.
What is Arch Biopartners Inc (ARCH) beta (volatility) score?
Arch Biopartners Inc has a beta of 1.721, suggesting it is more volatile than the market.
